- 同
- anti-IgE, Xolair
Related Links
- Design Patients were treated with omalizumab by using European dosing guidelines based on weight and serum total IgE level 30 for 12 weeks to minimize the IgE bound to FcεR1 on mast cells and basophils 31 (Fig 1). In week 12 ...
- ... associated with accidental exposure, a major concern among patients and their families. In addition, because omalilzumab neutralizes IgE of all specificities, our result with peanut suggests that rapid desensitization to other ...
Related Pictures
★リンクテーブル★
| リンク元 | 「mab」 |
「mab」
mab
- abciximab
- adahmumab
- adalimumab
- afelimomab
- alemtuzumab
- apolizumab
- arcitumomab
- basiliximab
- bevacizumab
- cantuzumab
- certolizumab
- cetolizumab
- cetuximab
- clenoliximab
- daclizumab
- デノスマブ denosumab 抗RANKL抗体
- eculizumab
- edrecolomab
- efalizumab
- epratuzumab
- galiximab
- gemtuzumab
- ibritumomab
- インフリキシマブ infliximab 抗TNF-α抗体 クローン病 Ph+ALL
- inotuzumab
- keliximab
- natalizumab
- nebacumab
- omalilzumab
- omalizumab
- oregovomab
- palivizumab
- panitumumab
- pertuzumab
- pexelizumab
- リツキシマブ rituximab：抗CD20抗体：慢性リンパ性白血病、B細胞リンパ腫